Tag: Bio-Path Holdings
November 21, 2019
Bio-Path’s Shares Dip on IND Application Approval
The FDA has approved Bio-Path's IND for its second drug candidate, but the news sent the company's shares down over... November 21, 2019
Bio-Path Holdings Receives FDA Clearance for BP1002
A Phase 1 clinical trial will now evaluate BP1002's ability to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia. August 26, 2019